Review Article

PPARγ and Its Role in Cardiovascular Diseases

Mini Chandra, Sumitra Miriyala, and Manikandan Panchatcharam

Department of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, USA

Correspondence should be addressed to Manikandan Panchatcharam; mpanch@lsuhsc.edu

Received 20 October 2016; Revised 28 December 2016; Accepted 9 January 2017; Published 24 January 2017

Academic Editor: Richard P. Phipps

Copyright © 2017 Mini Chandra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peroxisome proliferator-activated receptor Gamma (PPARγ), a ligand-activated transcription factor, has a role in various cellular functions as well as glucose homeostasis, lipid metabolism, and prevention of oxidative stress. The activators of PPARγ are already widely used in the treatment of diabetes mellitus. The cardioprotective effect of PPARγ activation has been studied extensively over the years making them potential therapeutic targets in diseases associated with cardiovascular disorders. However, they are also associated with adverse cardiovascular events such as congestive heart failure and myocardial infarction. This review aims to discuss the role of PPARγ in the various cardiovascular diseases and summarize the current knowledge on PPARγ agonists from multiple clinical trials. Finally, we also review the new PPARγ agonists under development as potential therapeutics with reduced or no adverse effects.

1. Introduction

Peroxisome proliferation-activated receptor gamma (PPARγ) is a ligand-activated transcription factor from the nuclear receptor family of peroxisome proliferator-activated receptors (PPARs). They contain a ligand binding domain which is hydrophobic and a type II zinc finger DNA-binding domain [1]. PPARs bind as heterodimers with the retinoid X receptor (RXR) which is 9-cis retinoic acid receptor. PPAR RXR heterodimers transactivate genes by binding specific sequences in the promoter regions of these genes. When a ligand activates PPARγ it results in subsequent activation of target genes as well as inhibition of the inflammatory response of transcription factors. In the absence of ligands, this PPAR RXR heterodimer binds to co-repressors and in turn suppresses the target genes [2, 3]. There are four isoforms of PPARγ detected in humans, PPARγ1, PPARγ2, PPARγ3 and PPARγ4 [4]. Out of these isoforms PPARγ1, 3 and 4 encode the same protein whereas PPARγ2 is expressed in adipose tissue only [5]. The location of human PPARγ gene has been identified as chromosome 3p25 [6]. In mice, the location is on chromosome 6 [7].

PPARγ is activated by both natural and synthetic ligands such as derivatives of prostaglandins like 15-deoxy-Delta12, 14-prostaglandin J2 [8], derivatives of fatty acid oxidation hydroxy octadecadienoic acid (HODE) which are components of oxidized low density lipoproteins (LDL) [9], lysophosphatidic acid (LPA) [10], Thiazolidinediones (TZD) like pioglitazone and rosiglitazone [8] and natural dietary substances found in the food [11].

PPARγ is highly expressed in adipocytes [12], vascular smooth muscle cells (VSMCs) [13], macrophages [14], cardiomyocytes [15] and endothelial cells. PPARγ activation serves a role in glucose homeostasis and adipogenesis in subcutaneous fat [16], regulating the metabolism of lipid in adipocytes, keeping oxidative stress in check as well as inhibiting apoptosis and maintaining endothelial function, cell proliferation and cell differentiation [17]. It also has a role against inflammation [18]. PPARγ activation results in reduced expression of factors such as TNF-alpha, IL-1 and resistin which are insulin resistance-inducing adipokines. In macrophages, PPARγ suppresses the inducible nitric oxide synthase (iNOS) upregulation and reactive oxygen species (ROS) production. These roles serve to benefit against many
diseases which are risk factors for cardiovascular disorders such as atherosclerosis, diabetes, hypertension, obesity and dyslipidemia.

2. PPARγ and Insulin Resistance

Insulin resistance such as seen in Type 2 diabetes, impaired glucose tolerance, and metabolic syndrome is a well-established risk factor for cardiovascular disease. PPARγ controls the genes encoding peptides or proteins involved in insulin resistance. PPARγ activators are commonly used in the treatment of type 2 diabetes showing certain abnormalities which are associated with the risk of cardiovascular disease such as increased glucose, insulin and triglyceride levels along with reduced levels of high-density lipoprotein cholesterol (HDL-C) and adiponectin levels [19], a hormone produced in white adipose tissue which has antioxidative, anti-inflammatory and vasodilator effects [20] and has been linked to cardiovascular diseases, insulin resistance states and obesity [21]. Other abnormalities include increased circulating levels of non-esterified fatty acids (NEFA) which are implicated in oxidative stress and induction of inflammatory response in the endothelium. They are associated with endothelial dysfunction and hypertension. High NEFA levels may also predispose cardiomyocytes to a ventricular arrhythmia [22].

PPARγ redistributes triacylglycerol from the subcutaneous fat and visceral fat [23] where the activators of PPARγ move the fat from the visceral adipose tissue, liver and muscles towards subcutaneous tissue by increasing insulin sensitivity in the peripheral and hepatic tissue thereby lowering the concentrations of plasma fatty acid [24]. There also occurs an improvement in the glycemic control. There also occurs improvement in the above-mentioned risk factors of diabetes-related risk of cardiovascular diseases such as lowering of triglycerides and plasma NEFA through its effect on the macrophages along with the increased HDL-C and adiponectin [25].

The most common activators of PPARγ are Thiazolidinedione (TZD) such as pioglitazone and rosiglitazone which are synthetic agonist ligands of PPARγ. One of the mechanisms of action of TZD is the prevention of the phosphorylation of PPARγ. High-fat diet activates the protein kinase cyclin-dependent kinase 5 (CDK5) activity which leads to the subsequent phosphorylation of PPARγ decreasing its insulin sensitizing effect. For the development of diabetes, PPARγ gets phosphorylated by CDK5 at serine 273 leading to alterations in many genes in the adipose tissue resulting in increased insulin resistance [26]. Recently, the role of CDK5 and extracellular signal-regulated kinases (ERK) was demonstrated in the phosphorylation of PPARγ by Banks et al. They created CDK5 knockout mice in the adipose tissue and demonstrated that in the absence of CDK5, there still occurs an increase in the phosphorylation of PPARγ at serine 273 due to direct effect of ERK. In the presence of CDK5, ERK is suppressed due to its action on ERK kinase (MEK) [27] (Figure 1(a)). TZDs block the phosphorylation of PPARγ by both CDK5 and ERK (Figure 1(b)).

Their data sheds new light to the regulation of PPARγ and another alternative to the treatment of Type 2 Diabetes. TZDs are already used in the treatment of type 2 diabetes [28]. They are used as monotherapy or as add-on therapy and result in improved insulin sensitivity demonstrating reduced insulin concentrations along with a decrease in the hemoglobin A1c (HbA1c) and fasting blood glucose [25, 29]. TZD also has been shown to increase serum levels of HDL-cholesterol and decrease triglycerides and LDL-cholesterol levels [30]. The decrease in NEFA is observed in both fasting and postprandial levels with decrease becoming apparent as early as 4 weeks of starting treatment [31], with the two TZDs rosiglitazone and pioglitazone showing similar reductions but greater when compared to treatments with metformin, sulfonylureas or statins [32]. TZD treatment doubles the concentration of circulating adiponectin produced by adipose tissue in insulin resistant states [21]. In the diabetic heart, Rosiglitazone demonstrates a protective role, by decreasing cardiac fibrosis and protection against apoptosis as well as improvement in the left ventricular diastolic dysfunction [33, 34]. Similarly, Pioglitazone showed an improvement in the worsening of ischemic preconditioning in the diabetic myocardium [35]. Though the role of TZDs as an insulin-sensitizing treatment conferring benefit to the cardiovascular system would, in theory, be of advantage in future treatments of cardiovascular events associated with high insulin resistance states, clinical trials have not been able to

---

Figure 1: (a) Phosphorylation of PPARγ by ERK and CDK5 which also suppresses ERK Kinase. (b) TZD blocking the access of ERK and CDK5.
support it. In the BARI-2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial which hypothesized that insulin-sensitizing treatment using TZD would result in greater cardiovascular benefit, lower mean HbA1c and fasting insulin levels was shown although it did not show decreased the occurrence of myocardial infarction (MI) or death upon follow-up 5 years later [36]. It is, however, notable that in the trial the use of multiple glycemic control agents makes it impossible to comment on the efficacy of the TZDs. As mentioned previously, the demonstration by Banks et al. of the involvement of ERK pathway in the phosphorylation of PPARγ in mice model [27] may offer an alternative to increasing the sensitivity of insulin as well lowering the occurrence of cardiovascular events by adding a kinase inhibitor thus increasing the effectiveness of TZDs.

3. Atherosclerosis, Vascular Disease and PPARγ

The proliferation of vascular smooth muscle cells and damage to endothelial cells resulting in the expression of adhesion molecules and ultimately leukocyte adhesion are important events in the development of atherosclerosis. Insulin resistance is implicated in the development of atherosclerosis [37]. There are many studies which demonstrate the beneficial role of PPARγ in limiting the progression of atherosclerosis as well as the acceleration of atherosclerosis with the knockout of PPARγ in macrophages [25]. PPARγ ligands are expressed in the atherosclerotic plaques [38] and have an effect on both these cells. Ligands of PPARγ decrease cytokines such as nitric oxide synthase, IL-6, and tumor necrosis factor α [14] thereby reducing the inflammatory response associated with atherosclerosis. The secretion of metalloproteinases (MMPs) especially MMP-9, by macrophages is responsible for the rupture of atherosclerotic plaques by degrading the extracellular matrix. PPARγ in both vascular smooth muscle cells and macrophages reduces the expression of MMP thereby hindering the migration of vascular smooth muscle cells thus preventing the plaques from becoming vulnerable to rupture [13, 14]. In 2000, Li et al. demonstrated the inhibition of atherosclerosis progression in LDL receptor-deficient mice using rosiglitazone. The reduction in the atherosclerotic lesion was seen in male mice but did not show similar results in female mice [39]. This highlights the importance of conducting more gender specific studies for actions of PPARγ. To determine whether the improvement seen by Li et al. was due to effect of TZD on the artery itself or on the metabolic system, Collins et al. used LDL receptor-deficient male mice and fed them two different diets, one group was fed high-fat diet and the other group was on high fructose diet, along with 3 months treatment with troglitazone, a PPARγ agonist. The results showed a decrease of the lesion in both groups but only the high-fat diet group of mice showed an increase in insulin sensitivity. Thus the conclusion can be made that the role of TZD in decreasing insulin resistance and decreasing atherosclerotic plaques are independent of each other [40]. In 2009, Nakaya et al. reported prevention of atherosclerotic progression with pioglitazone treatment though the existing lesion was not reversed nor was any improvement seen in advanced atherosclerotic lesions in mice models of LDLR receptor deficiency (LDLR−/−) [41]. In 2011, reduction in lesion inflammation was demonstrated in rabbits given pioglitazone treatment for 3 months [42].

Insulin resistance is associated with the development of atherosclerosis. The risk of occurrence of an atherosclerotic event is related to the severity of hyperglycemia as observed by the HbA1c levels [43]. Though in clinical trials such as the PROACTIVE (Prospective Pioglitazone Clinical Trial in Macrovascular Events) a PPARγ agonist such as pioglitazone did not show a correlation between its effect on HbA1c and risk of development of cardiovascular disease [44].

Effects of PPARγ agonist on carotid atherosclerosis has been varied. A double blind study done on patients with normal glucose tolerance and stable coronary artery disease showed TZD, pioglitazone stimulates the production of endothelial progenitor cells in vascular injury promoting endothelial repair [45]. The STARR (Study of Atherosclerosis with Ramipril and Rosiglitazone) study compared the carotid artery medial thickness progression in rosiglitazone group compared with placebo. After a study period of 3 years there was a trend towards less carotid artery intimal thickness progression in the rosiglitazone group, however, it was not statistically significant [46]. Another trial comparing carotid artery intimal thickness between two study groups on pioglitazone verses glimepiride (Chicago trial) showed stable carotid artery intimal thickness in pioglitazone group, however, progression of intimal thickness was seen in the glimepiride group which was statistically significant [47]. One long-term study of pioglitazone compared with glimepiride has shown the reversal of carotid atheroma volume in the pioglitazone group. In contrast, the carotid artery atheroma showed progression in the glimepiride group (PERISCOPE trial; Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prosp ective Evaluation) [48]. Though not conclusive, these studies taken together do point towards the beneficial effect of TZDs. Statins, which are used in the treatment of atherosclerosis result in an increase in PPARγ activity by activating extracellular signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) pathways [49]. Lobeglitazone is a new PPARγ agonist shown to have anti-atherosclerotic properties. It can be used in the treatment of patients with a cardiovascular disease associated with diabetes. A significant decrease in the atherosclerotic lesion was observed in apolipoprotein E gene knockout mice (ApoE−/−) on high cholesterol and high-fat diet with the use of Lobeglitazone, as well as reduced formation of neointima after balloon injury to the carotid artery [50].

Endothelial PPARγ regulates the gene expressions of NADPH oxidase, superoxide dismutase and catalase thus increasing vasodilation [51]. The treatment with TZD resultant activation of PPARγ in adipocytes and inflammatory cells in the adipose tissue inhibits release of inflammatory mediators along with the reduction in local inflammation [52]. ROS can lead to alteration of vascular function [53] thus playing a role in the development of cardiovascular
disorders. Oxidative stress reduces the expression of PPARγ in the vascular endothelial cells [54]. In turn, PPARγ has a protective effect on the cardiomyocytes by upregulation of the antiapoptotic Bcl-2 protein against oxidative stress [55].

It is worth noting that the direct effect of PPARγ on the heart leads to heart failure. This was demonstrated in transgenic mice models of PPARγ created by Son et al., which expressed PPARγ1 in the heart. An increase in triglyceride uptake and increased fatty acid oxidation was observed and the mice developed dilated cardiomyopathy with the production of damaged mitochondria [56] when treated with PPARγ agonist TZD rosiglitazone.

4. Ischemia-Reperfusion Injury and PPARγ

Previous studies using rat models of ischemia-reperfusion injury have demonstrated a reduction in myocardial damage with the use of TZDs [57]. The TZDs rosiglitazone, pioglitazone, and ciglitazone, all resulted in a decrease of myocardial infarct size.

Rosiglitazone has a cardio protective effect in both non-diabetic and diabetic rats limiting the damage to the heart following ischemia/reperfusion injury via inhibition of Jun NH (2)-terminal kinase phosphorylation [58]. Another mechanism by which Rosiglitazone provides cardioprotection is by selective overexpression of angiotensin type 2 along with the inhibition of p42/44 MAPK pathway. This effect was demonstrated to be separate from the insulin-sensitizing effect of Rosiglitazone [59]. Yet another mechanism for reduction of heart injury due to ischemia was observed in hypercholesterolaemic rats. Rosiglitazone reduced the increased activity of myeloperoxidase induced by hypercholesterolemia thus resulting in a decrease in infarct size [60]. The TZD ciglitazone results in decreased myocardial damage, infiltration of neutrophils and cytokine production by increasing DNA binding of PPARγ and decreasing the activation of nuclear factor kB (Figure 2) [61]. Pioglitazone also has protective effect against MI, exhibiting reduced infarct size in rabbit model via activation of PPARγ, PI-3 kinases, eNOS and Akt pathways [62].

5. Limitation of PPARγ as a Therapeutic Measure in Cardiovascular Disease

Though treatment with activators of PPARγ seems to have a favorable effect on the risk factors for cardiovascular disease, it also has adverse effects on the cardiovascular system which mitigates its beneficial effects thus limiting their widespread use in patients with cardiovascular risk.

In humans, the treatment with PPARγ agonist TZD leads to increase the risk of developing edema and congestive heart failure which is thought to be due to the retention of salt and water (Rubenstrunk, Hanf et al. 2007). The mechanism by which TZD causes fluid retention may be due to the increased transcription of SGK1 (Serum/Glucocorticoid-Regulated Kinase-1) which activates the renal epithelial sodium channels [63]. Currently, the increase in vascular permeability due to increased levels of vascular endothelial growth factor in these patients is known [64]. In a study by Tang et al., no association was observed between severity of heart failure and risk of fluid retention [65], though much research still needs to be conducted before making use of TZDs in clinical settings. PPARγ are also responsible for weight gain due to increase in the adipose tissue mass [66], may increase low-density lipoproteins cholesterol concentration [67], promote the onset of ventricular fibrillation in severe ischemia [68], and modify cardiac ion channels promoting arrhythmia [69]. Even though it has been shown to decrease the progression of atherosclerosis [70], pioglitazone has also been shown to develop plaque necrosis [71] in advanced atherosclerosis in a study done on LDL receptor-deficient mice. It has been reported that treatment with rosiglitazone is linked with an increase in MI in humans [72, 73]. Though in the RECORD (Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes) trial, rosiglitazone was shown to be linked with risk of heart failure and not MI [74]. Unlike rosiglitazone, pioglitazone does not induce cardiac hypertrophy as seen in mice [75]. Pioglitazone has a more positive effect than rosiglitazone on lipid profile with improvement in LDL and triglycerides in patients with diabetes and dyslipidemia [67]. It has also shown a positive effect on the endothelial progenitor cells by increasing their number in patients with coronary artery disease which help in improving vascular function [45]. Due to the possibility of developing cardiac dysfunction with the use of TZD in patients with congestive heart failure, their use in these patients is avoided.

Patients with congestive heart failure are prone to develop heart failure following PPARγ therapy as a result of increased plasma volume. It is notable however that in both animal and clinical studies the resultant heart failure has not been linked to the effect of TZD on left ventricular systolic function [76]. More recently, TZD has been associated with bone loss [77], with the use rosiglitazone shown to be responsible for an increase in fractures in diabetic patients [78].
6. Clinical Trials to Determine the Efficacy of PPARγ Activators

6.1. IRIS Trial. The IRIS (insulin resistance intervention after stroke) trial is a randomized trial to determine the efficacy of pioglitazone in patients with no history of heart failure, who are insulin resistant and non-diabetic, having a history of recent transient ischemic attack or ischemic stroke. Insulin resistance criteria was an HOMA-IR (Homeostatic Model Assessment-Insulin Resistance) index higher than 3. The hypothesis of this trial was that Pioglitazone will decrease the rate of myocardial infarction and stroke in the selected group. The results of this trial are demonstrated lowered rates of myocardial infarction, stroke, and death in patients receiving pioglitazone. These subjects showed improvement in blood pressure, improved levels of triglycerides, HDL cholesterol and insulin sensitivity. Moreover, the rate of heart failure in the pioglitazone group was not higher than the placebo group. This trial provides information which may be of great importance due to the fact that this trial is in patients who are not diabetic thereby reducing the chances of confounding results by multiple diabetic therapies. This study also determines whether the use of pioglitazone in patients on statins is beneficial.

7. PROACTIVE

PROACTIVE (Prospective Pioglitazone Clinical Trial in Macrovascular Events) trial compared pioglitazone with a placebo in the type 2 diabetic patients with HbA1c greater than 6.5% who were also suffering from the atherosclerotic disease in a double-blind study, with a mean follow-up of 34.5 months. It sought to determine the effect of pioglitazone in reducing the incidence of macrovascular complications. Pioglitazone did not have a significant effect on the primary and main secondary endpoints in the patients treated with insulin though there was a lowering in the mean insulin dose in patients on pioglitazone as compared to those on placebo with discontinuation of insulin in 9% pioglitazone patients as compared to 2% placebo patients [79]. Furthermore, in a subgroup analysis done previously, pioglitazone significantly reduced the occurrence of MI by 28% in patients with prior history of MI [80]. Although pioglitazone did significantly reduce the risk of myocardial infarction, it also increased the risk of edema in the subjects. These studies demonstrate a positive efficacy of pioglitazone in cardiovascular disease but a loner observation would be more conclusive. Also, due to the use of other treatments for diabetes in an imbalanced manner in terms of frequency and dosage may also have affected the outcome of study if they also affect the cardiovascular system. Another point of note in these trials is the use of statin in only half of the patients studied. The risk of death was reduced only by 5% in patients treated with a statin and given pioglitazone but was 25% in patients not on statin [44].

8. RECORD Trial

RECORD trial tested the use of rosiglitazone as an add-on therapy in patients with type 2 diabetes not controlled by sulfonylurea or metformin alone with mean HbA1c of 7.9%. The group treated with rosiglitazone exhibited higher levels of LDL-C, HDL-C and weight and lower levels. After a mean follow-up of 5.5 years, the group with rosiglitazone had a higher frequency of heart failure. The higher use of statins and diuretics in patients on rosiglitazone as well as the lower event rate and subsequent low statistical power due to lack of follow-up are limitations of this trial [81]. The RECORD results do not show a significant difference between metformin/sulfonylurea group and rosiglitazone group in terms of myocardial infarction, stroke or cardiovascular death. Although the risk of heart failure is relatively small, it is nevertheless an important concern. This reinforces the importance of not using TZDs in patients with heart failure.

9. DREAM Trial

The DREAM (Diabetes Reduction Assessment with Ramipril and rosiglitazone Medication) trial was done to determine the effect of 8 mg per day rosiglitazone and/or Ramipril on patients with impaired glucose tolerance or impaired fasting glucose but with no history of cardiovascular disease. Follow-up after 3 years showed a significant reduction in the development of new onset diabetes in patients on rosiglitazone although it was also associated with increased development of heart failure as compared to patients on Ramipril [82]. This study demonstrates a positive role of rosiglitazone in reducing or even eliminating the risk of developing diabetes in obese subjects. However, the short follow-up period of this trial, as well as exclusion of cardiovascular disease history in subjects, limit the conclusions that can be drawn about rosiglitazone and its cardiovascular effects. The heart failure observed in the patients receiving rosiglitazone may be due to the effect of the drug on the kidney resulting in fluid overload a subsequent heart failure in some individuals.

10. ACT NOW Trial

The ACT NOW (Actos Now for the prevention of Diabetes) trial sought to determine the effect of pioglitazone in the prevention of new-onset diabetes in patients with impaired glucose tolerance. Patients either received placebo or 45 mg of pioglitazone. After a 2.2-year mean follow-up, a significant reduction in the fasting glucose levels was observed in the pioglitazone group, as well as reduced levels of HbA1c and increase in the levels of HDL-C. 5% of people progressed to diabetes in the pioglitazone group as compared to 16.7% seen in the placebo group. However, the pioglitazone group did have the adverse effect of increased incidence of edema and weight gain [83]. Therefore, in patients with impaired glucose tolerance, pioglitazone reduced the risk of diabetes, improved HDL cholesterol levels and liver enzymes but was associated with edema and weight gain.

11. ADOPT Trial

A Diabetes Outcome Progression Trial (ADOPT) used patients with newly diagnosed type 2 diabetes to determine
the glycemic durability of three drugs to be used as first-line treatment namely, rosiglitazone, metformin, and glyburide. Treatment was for a median of 4 years with primary outcome set as the failure of monotherapy with fasting blood glucose level more than 10 mmol/L after 6 weeks of treatment. Follow-up at 5 years revealed a lower number of failure in rosiglitazone-treated patients (15%) with low HbA1c and high insulin sensitivity though again was associated with weight gain and edema [84]. This study was significant because it demonstrates that rosiglitazone maintained targeted sugar level for a longer period when compared to metformin and glyburide.

12. Meta-analysis of Clinical Trials

The meta-analysis of controlled trials of pioglitazone shows a reduction in the risk of MI, stroke or death in patients with type 2 diabetes mellitus [85, 86]. On the other hand, a meta-analysis of trials with rosiglitazone, it has been linked to an increased risk of MI though the associated mortality is still low [87]. Due to this reason, rosiglitazone use is limited in the United States whereas it is not used in Europe [88].

13. Comparative Analysis

No randomized trial has been conducted to compare the two TZDs pioglitazone and rosiglitazone although it has been compared in cohort studies, treatment with rosiglitazone is associated with higher rates of cardiovascular events [89–91]. Upon meta-analysis of observational studies, rosiglitazone was associated with higher incidence of adverse cardiovascular events such as congestive heart failure, MI, and death [92].

These trials have been very important in providing evidence to support the decisions made in choosing therapy. Studies like ADOPt which compare a TZD with commonly used antidiabetic drugs provide valuable new information to help guide future treatments. Although rosiglitazone is associated with the adverse effect of edema and weight gain, metformin and glyburide are also associated with gastrointestinal effects and weight gain respectively. However, it was shown that hyperglycemia associated with diabetes can be slowed using TZD.

Despite such positive effects, the contradictory results of trials, as well as the adverse effects of TZDs, most important being development of congestive heart failure, have limited the use of TZDs. On one hand, TZDs has a role in increasing the incidence of heart failure due to fluid retention. On the other hand, studies like PROACTIVE also suggest a beneficial role of TZDs in reducing cardiovascular disease. Similarly, DREAM trial showed an increase in heart failure but ADOPt trial showed no difference in the incidence of heart failure between rosiglitazone and other antidiabetic drugs.

14. New PPARγ Activators and Future Therapeutic Measures

Dual PPAR alpha and γ activators are being developed to combine the HDL-C raising and triglyceride lowering effect of PPAR alpha with the insulin sensitivity increasing the effect of PPARγ. PPARα activation upregulates the genes responsible for fatty acid transport and activation. Ligands for PPARα are used to treat hyperlipidemia. In this regard, Glitazar class of drugs were developed which activated both the isoforms of PPAR but the increased incidence of adverse effects prevented further research [93, 94]. Another dual activator by the name of aleglitazar has completed phase II trials [95]. The study SYNCHRONY, a phase II randomized trial to determine the cardiovascular disease risk of aleglitazar in type 2 diabetic patients [96], demonstrated a significant decrease in levels of HbA1c as well as on levels of triglyceride and LDL. In addition, an increase in HDL cholesterol was also found. However, in the phase III study known as ALECARDIO, a randomized clinical trial to determine the protective effect of aleglitazar in type 2 diabetic patients who have suffered an acute coronary syndrome did not find a reduction in the incidence of myocardial infarction or cardiovascular death with the use of aleglitazar. On the contrary, an increase in the risk of heart failure, bone fractures, gastrointestinal hemorrhage and renal function was observed.

Currently, the development of partial PPARγ agonists is underway in the hopes that unlike TZDs which are full PPARγ agonists, selective partial agonists will be associated with lesser adverse effects such as fluid retention, heart failure, and so forth while retaining the insulin sensitizing effects. New specific PPARγ agonist S26948, displays a reduction in atherosclerotic lesions along with anti-diabetic effects [97]. INT-131 besylate is another selective peroxisome proliferator activated receptor γ modulator (SPPARM) evaluated in a study to determine its safety and efficacy in type 2 diabetes mellitus. A reduction in the fasting plasma glucose was observed without fluid retention or weight gain when compared to a similar model of rosiglitazone. At a dosage of 1 mg the fasting glucose reduced from 163 to 142 mg/dL without any change in the levels of NEFA, adiponectin or fasting glucose. Upon increasing the dose to 10 mg the reduction in glucose was from 183 to 137 mg/dL with significant lowering of NEFA, adiponectin, and insulin. However, an increase in weight gain and edema, as well as decrease in hematocrit levels, was also observed a phase II study using the 10 mg dosage, therefore, the advantage of using partial PPARγ activators is yet to be determined with further studies [98]. SR1664 is a new anti-diabetic compound without the side effects of fluid retention and weight gain. Similar to rosiglitazone it blocked the phosphorylation of PPARγ via CDK5 and is classified as a non-agonist inhibitor of CDK5 without adipogenic function in vitro [99].

The effect of a new TZD, Rivoglitazone, on the control of lipids and glucose has been compared to pioglitazone in a double-blind randomized control trial in Chinese patients with type 2 diabetes. It has been reported to be a safe and efficacious TZD-associated with improvement in glycemic control but further studies are still to be conducted [100].
Another new TZD PPARγ partial agonist, balaglitazone is currently under evaluation in phase III clinical trial in US and Europe which shows glycemic control as an add-on to insulin therapy with a lower incidence of fat accumulation and fluid retention when compared to pioglitazone [101]. A new dual PPARs and PPARγ agonist known as Saroglitazar, with a higher activity for PPARs and moderate PPARγ activity, has been approved for the treatment of type 2 diabetes in India in order to control diabetic dyslipidemia [102]. However, further studies are still to be conducted before any conclusions can be made on its effect on the cardiovascular system.

15. Conclusions

PPARγ plays an important role in cardiovascular diseases but much research is still needed to establish its function in the cardiovascular system. PPARγ agonists confer benefits in diabetes and atherosclerosis, known risk factors associated with cardiovascular disease. They are beneficial as therapeutic agents resulting in improved insulin resistance, reduced glucose levels in the blood as well as reduced inflammation. However, they also have deleterious effects such as increased higher risk incidence of congestive heart failure. Therefore, their use is limited in clinical settings. At present, the use of PPARγ agonists among patients is at the discretion of the physicians. Further research on PPAR physiology and pharmacology, as well the knowledge gained by the use of PPARγ agonists, both known and under development, should assist in the development of newer and safer therapeutic agents.

Competing Interests

The authors declare that they have no competing interests.

References

[1] A. Abbas, J. Blandon, J. Rude, A. Elfar, and D. Mukherjee, "PPAR-γ agonist in treatment of diabetes: cardiovascular safety considerations," Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 10, no. 2, pp. 124–134, 2012.
[2] D. J. Mangeldorf and R. M. Evans, "The RXR heterodimers and orphan receptors," Cell, vol. 83, no. 6, pp. 841–850, 1995.
[3] S. Ogawa, J. Lozach, K. Jepsen et al., "A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 40, pp. 14461–14466, 2004.
[4] N. Wang, R. Yin, Y. Liu, G. Mao, and F. Xi, "Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update," Circulation Journal, vol. 75, no. 3, pp. 528–535, 2011.
[5] M. Lehrke and M. A. Lazar, "The many faces of PPARγ," Cell, vol. 123, no. 6, pp. 993–999, 2005.
[6] M. E. Greene, B. Blumberg, O. W. McBride et al., "Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping," Gene Expression, vol. 4, no. 4-5, pp. 281–299, 1995.
[7] P. S. Jones, R. Savory, P. Barratt et al., "Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes," European Journal of Biochemistry, vol. 233, no. 1, pp. 219–226, 1995.
[8] R. M. Touyz and E. L. Schiffrin, "Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications," Vascular Pharmacology, vol. 45, no. 1, pp. 19–28, 2006.
[9] L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, "Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ," Cell, vol. 93, no. 2, pp. 229–240, 1998.
[10] T. M. McIntyre, A. V. Pontsler, A. R. Silva et al., "Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 131–136, 2003.
[11] A. Majdalawieh and H.-S. Ro, "PPARγ/γ and LXRα face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1," Nuclear receptor signaling, vol. 8, p. e004, 2010.
[12] M. Adams, C. T. Montague, J. B. Prins et al., "Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation," The Journal of Clinical Investigation, vol. 100, no. 12, pp. 3149–3153, 1997.
[13] N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, "Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells," Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998.
[14] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, "The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation," Nature, vol. 391, no. 6662, pp. 79–82, 1998.
[15] H. Takano, T. Nagai, M. Asakawa et al., "Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes," Circulation Research, vol. 87, no. 7, pp. 596–602, 2000.
[16] B. M. Spiegelman, "Peroxisome proliferator-activated receptor gamma: a key regulator of adipogenesis and systemic insulin sensitivity," European journal of medical research, vol. 2, no. 11, pp. 457–464, 1997.
[17] R. Kapadia, J.-H. Yi, and R. Vemuganti, "Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists," Frontiers in Bioscience, vol. 13, no. 5, pp. 1813–1826, 2008.
[18] P. Tontonoz and B. M. Spiegelman, "Fat and beyond: the diverse biology of PPARγ," Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008.
[19] K. B. Doshi, S. R. Kashyap, D. M. Brennan, B. M. Hoar, L. Choo, and B. J. Hoogwerf, "All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study," Diabetes, Obesity and Metabolism, vol. 11, no. 2, pp. 102–108, 2009.
[20] X. Hui, K. S. Lam, P. M. Vanhoutte, and A. Xu, "Adiponectin and cardiovascular health: an update," British Journal of Pharmacology, vol. 165, no. 3, pp. 574–590, 2012.
[21] N. Riera-Guardia and D. Rothenbacher, “The effect of thiazolidinediones on adiponectin serum level: a meta-analysis,” Diabetes, Obesity and Metabolism, vol. 10, no. 5, pp. 367–375, 2008.

[22] J. S. Charnock, “Lipids and cardiac arrhythmia,” Progress in Lipid Research, vol. 33, no. 4, pp. 355–385, 1994.

[23] W. T. Festuccia, P.-G. Blanchard, V. Turcotte et al., “Depot-specific effects of the PPARα agonist rosiglitazone on adipose tissue glucose uptake and metabolism,” Journal of Lipid Research, vol. 50, no. 6, pp. 1185–1194, 2009.

[24] A. B. Mayerson, R. S. Hundal, S. Dufour et al., “The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes,” Diabetes, vol. 51, no. 3, pp. 797–802, 2002.

[25] J. V. Huang, C. R. Greyson, and G. G. Schwartz, “PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty,” Journal of Lipid Research, vol. 53, no. 9, pp. 1738–1754, 2012.

[26] J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5,” Nature, vol. 466, pp. 431–435, 2011.

[27] A. S. Banks, F. E. McAlister, J. P. G. Capore et al., “An ERK/Cdk5 axis controls the diabeticogenic actions of PPARγ,” Nature, vol. 517, pp. 391–395, 2015.

[28] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.

[29] G. Perriello, S. Pampanelli, C. Di Pietro, and P. Brunetti, “Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes,” Diabetic Medicine, vol. 23, no. 3, pp. 246–252, 2006.

[30] A. Komatsu and K. Nose, “Effects of PPARgamma agonist on dyslipidemia and atherosclerosis,” Nippon Rinsho, vol. 68, no. 2, pp. 294–298, 2010.

[31] F. Abbasi, N. K. C. Lima, and G. M. Reaven, “Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone,” Metabolism, vol. 58, no. 3, pp. 373–378, 2009.

[32] F. Abbasi, Y.-D. I. Chen, H. M. F. Farin, C. Lamendola, and G. M. Reaven, “Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects,” The American Journal of Cardiology, vol. 102, no. 1, pp. 64–69, 2008.

[33] A. Baraka and H. AbdelGawad, “Targeting apoptosis in the heart of streptozotocin-induced diabetic rats,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 15, no. 2, pp. 175–181, 2010.

[34] S.-H. Ihm, K. Chang, H.-Y. Kim et al., “Peroxisome proliferator-activated receptor-γ activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor,” Basic Research in Cardiology, vol. 105, no. 3, pp. 399–407, 2010.

[35] H. Sasaki, K. Ogawa, M. Shimizu et al., “The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats,” International Heart Journal, vol. 48, no. 5, pp. 623–635, 2007.

[36] R. L. Frye, P. August, M. M. Brooks et al., “A randomized trial of therapies for type 2 diabetes and coronary artery disease,” The New England Journal of Medicine, vol. 360, no. 24, pp. 2503–2515, 2009.

[37] A. D’Souza, M. Hussain, F. C. Howarth, N. M. Woods, K. Bidasee, and J. Singh, “Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart,” Molecular and Cellular Biochemistry, vol. 331, no. 1-2, pp. 89–116, 2009.

[38] N. Marx, G. Sukhova, C. Murphy, P. Libby, and J. Plutzky, “Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro,” American Journal of Pathology, vol. 153, no. 1, pp. 17–23, 1998.

[39] A. C. Li, K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass, “Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice,” The Journal of Clinical Investigation, vol. 106, no. 4, pp. 523–531, 2000.

[40] A. R. Collins, W. P. Meehan, U. Kintsch et al., “Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 365–371, 2001.

[41] H. Nakaya, B. D. Summers, A. C. Nicholson, A. M. Gotto Jr., D. P. Hajjar, and J. Han, “Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARγ ligand pioglitazone,” American Journal of Pathology, vol. 174, no. 6, pp. 2007–2014, 2009.

[42] E. Vucic, S. D. Dickson, C. Calcagno et al., “Pioglitazone modulates vascular inflammation in atherosclerotic rabbits: noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging,” JACC: Cardiovascular Imaging, vol. 4, no. 10, pp. 1100–1109, 2011.

[43] I. M. Stratton, A. I. Adler, H. A. W. Neil et al., “Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study,” British Medical Journal, vol. 321, pp. 405–410, 2000.

[44] E. Ferrannini, D. J. Betteridge, J. A. Dormandy et al., “High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive,” Diabetes, Obesity and Metabolism, vol. 13, no. 8, pp. 759–764, 2011.

[45] C. Werner, C. H. Kamani, C. Gesch, M. Böhm, and U. Laufs, “The peroxisome proliferator–activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance,” Diabetes, vol. 56, no. 10, pp. 2609–2615, 2007.

[46] E. M. Lonn, H. C. Gerstein, P. Sheridan et al., “Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone),” Journal of the American College of Cardiology, vol. 53, no. 22, pp. 2028–2035, 2009.

[47] M. H. Davidson, C. A. Beam, S. Haffner, A. Perez, R. Dagostino, and T. Mazzone, “Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 9, pp. 1873–1876, 2010.

[48] S. E. Nissen, S. J. Nicholls, K. Wolski et al., “Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE
randomized controlled trial,” JAMA, vol. 299, no. 13, pp. 1561–1573, 2008.

[49] M. Yano, T. Matsumura, T. Senokuchi et al., “Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-activated cyclooxygenase-2 expression in macrophages,” Circulation Research, vol. 100, no. 10, pp. 1442–1451, 2007.

[50] S. Lim, K.-S. Lee, J. E. Lee et al., “Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis,” Atherosclerosis, vol. 243, no. 1, pp. 107–119, 2015.

[51] P. Ketewat Somkron and C. D. Sigmund, “Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma,” Current Opinion in Nephrology and Hypertension, vol. 24, no. 2, pp. 123–130, 2015.

[52] A. Foryst-Ludwig, M. Hartge, M. Clemenz et al., “PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice,” Cardiovascular Diabetology, vol. 9, article no. 64, 2010.

[53] A. San Martín, P. Díaz, A. Dikalov et al., “Rosiglitazone inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury,” The FASEB Journal, vol. 81, no. 2, pp. 344–352, 2009.

[54] B. Molavi, J. Chen, and J. L. Mehta, “Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 291, no. 2, pp. H687–H693, 2006.

[55] H.-R. Liu, L. Tao, E. Gao et al., “Rosiglitazone inhibits hypercholesterolemia-induced myeloperoxidase upregulation—a novel mechanism for the cardioprotective effects of PPAR agonists,” Cardiovascular Research, vol. 81, no. 2, pp. 344–352, 2009.

[56] B. Zingarelli, P. W. Hake, P. Mangeskar et al., “Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-γ ligands, 15-deoxy-Δ12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-κB, heat shock factor 1, and Akt,” Shock, vol. 28, no. 5, pp. 554–563, 2007.
[76] N. Narang, S. I. Armstead, A. Stream et al., “Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment," *Diabetes and Vascular Disease Research*, vol. 8, no. 2, pp. 101–108, 2011.

[77] T. P. Burris, S. A. Bushby, and P. R. Griffin, “Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity," *Chemistry and Biology*, vol. 19, no. 1, pp. 51–59, 2012.

[78] W. Wei, X. Wang, M. Yang, L. C. Smith, and P. C. Dechow, “PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss," *Cell Metabolism*, vol. 11, no. 6, pp. 503–516, 2010.

[79] B. Charbonnel, R. DeFronzo, J. Davidson et al., “Rosiglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19),” *Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 5, pp. 2125–2135, 2009.

[80] E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, and A. M. Skene, “The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. results from the PROactive (PROactive 05) Study," *Journal of the American College of Cardiology*, vol. 49, no. 17, pp. 1772–1780, 2007.

[81] P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial," *The Lancet*, vol. 373, no. 9681, pp. 2125–2135, 2009.

[82] H. C. Gerstein, S. Yusuf, R. R. Holman et al., “Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial," *The Lancet*, vol. 368, no. 9541, pp. 1096–1105, 2006.

[83] R. A. DeFronzo, D. Tripathy, D. C. Schwenke et al., “Pioglitazone for diabetes prevention in impaired glucose tolerance," *The New England Journal of Medicine*, vol. 364, no. 12, pp. 1104–1115, 2011.

[84] S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy," *New England Journal of Medicine*, vol. 355, no. 23, pp. 2427–2443, 2006.

[85] A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen, “Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials," *The Journal of the American Medical Association*, vol. 298, no. 10, pp. 1180–1188, 2007.

[86] E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini, and N. Marchionni, “Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials," *Diabetes, Obesity and Metabolism*, vol. 10, no. 12, pp. 1221–1238, 2008.

[87] S. E. Nissen and K. Wolski, “Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality," *Archives of Internal Medicine*, vol. 170, no. 14, pp. 1191–1201, 2010.

[88] J. Woodcock, J. M. Sharfstein, and M. Hamburg, “Regulatory action on rosiglitazone by the U.S. food and drug administration," *New England Journal of Medicine*, vol. 363, no. 16, pp. 1489–1491, 2010.

[89] N. Ziyadeh, A. T. McAfee, C. Koro, J. Landon, and K. Arnold Chan, “The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database," *Clinical Therapeutics*, vol. 31, no. 11, pp. 2665–2677, 2009.

[90] F.-Y. Hsiao, W.-F. Huang, Y.-W. Wen, P.-F. Chen, K. N. Kuo, and Y.-W. Tsai, “Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473000 patients using the national health insurance database in Taiwan," *Drug Safety*, vol. 32, no. 8, pp. 675–690, 2009.

[91] Z. A. Habib, L. Tzogias, L. S. Havstad et al., “Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis," *Pharmacoepidemiology and Drug Safety*, vol. 18, no. 6, pp. 437–447, 2009.

[92] Y. K. Loke, C. S. Kwook, and S. Singh, “Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies," *BMJ*, vol. 342, no. 7799, Article ID d1309, p. 692, 2011.

[93] P. Balakumar, M. Rose, S. S. Ganti, P. Krishnan, and M. Singh, “PPAR dual agonists: are they opening Pandora’s Box?" *Pharmacological Research*, vol. 56, no. 2, pp. 91–98, 2007.

[94] L. M. Younk, L. Uhl, and S. N. Davis, “Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk," *Expert Opinion on Drug Metabolism and Toxicology*, vol. 7, no. 6, pp. 753–763, 2011.

[95] B. C. Hansen, X. T. Tigno, A. Bénardreau, M. Meyer, E. Sebokova, and J. Mizrahi, “Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome," *Cardiovascular Diabetology*, vol. 10, article no. 7, 2011.

[96] R. R. Henry, A. M. Lincoff, S. Mudalair, M. Rabbia, C. Chognot, and M. Herz, “Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study," *The Lancet*, vol. 374, no. 9684, pp. 126–135, 2009.

[97] M. C. Carmona, K. Louche, B. Lefebvre et al., “S 26948: a new specific peroxisome proliferator-activated receptor γ modulator with potent antidiabetes and antiatherogenic effects," *Diabetes*, vol. 56, no. 11, pp. 2797–2808, 2007.

[98] F. L. Dunn, L. S. Higgins, J. Fredrickson, and A. M. Depaoli, “Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes," *Journal of Diabetes and its Complications*, vol. 25, no. 3, pp. 151–158, 2011.

[99] J. H. Choi, A. S. Banks, T. M. Kamenecka et al., “Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation," *Nature*, vol. 477, no. 7365, pp. 477–481, 2011.

[100] A. P. S. Kong, A. Yamasaki, R. Ozaki et al., “A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes," *Diabetes, Obesity and Metabolism*, vol. 13, no. 9, pp. 806–813, 2011.

[101] R. Agrawal, P. Jain, and S. N. Diskhit, “Balaglitzase: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist," *Mini-Reviews in Medicinal Chemistry*, vol. 12, no. 2, pp. 87–97, 2012.

[102] R. Agrawal, “The first approved agent in the Glitazar’s class: Saroglitazar," *Current Drug Targets*, vol. 15, no. 2, pp. 151–155, 2014.